Overview

Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)

Status:
Not yet recruiting
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, interventional, non-randomized study among patients with a relapsed or refractory Wilms tumor. The study will aim to assess efficacy of metronomic chemotherapy, in terms of disease control after two cycles of metronomic chemotherapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Centre Oscar Lambret
Treatments:
Etoposide
Irinotecan
Isotretinoin
Temozolomide
Tretinoin
Vincristine